Skip to main content
. 2023 Mar 7;15(4):e16715. doi: 10.15252/emmm.202216715

Figure 2. RANK tumor expression associates with poor survival in ER− BC and RANKL inhibition improves response to chemotherapy.

Figure 2

  • A
    Bubble matrix represents GSEA results of pathways associated with RANK protein expression in the METABRIC collection classified by ER expression. The matrix illustrates the NES and FDR values (empty bubbles FDR > 0.25). Color legend indicates the main biological process associated.
  • B
    Percentage of RANK+ tumors in indicated ER− collections.
  • C
    DMFS and BCSS according to RANK expression.
  • D
    Forest plots showing HR, 95% CI and uni or multivariate p‐values for the indicated survival parameters.
  • E
    DMFS and BCSS after chemotherapy (anthracyclines/taxanes) according to RANK expression.
  • F, G
    Tumor growth curves ((π × length × width2)/6) of the indicated PDXs after treatment with RANK‐Fc, denosumab (DNS) or mock (CTRL), alone (F) or in combination with docetaxel (DTX) (G). (G) Bottom left shows tumor growth/regression during DTX/RANKL‐inhibitor treatment for STG139‐M. Bottom right shows the tumor relapse in these same mice after removal of the treatment. Each thin curve represents one single tumor, and each thick curve represents the mean of all tumors implanted. Linear regression analysis and two‐tailed p‐value are shown.

Data information: (B, C, E) Total number of analyzed patients per parameter and p‐values (Log‐rank test (Mantel‐Cox)) are indicated.